Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Stein, S., Zhao, R., Haeno, H., Vivanco, I. & Michor, F. (2018). Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. Plos comput biol, Vol.14 (1), p. e1005924.  show abstract

Oldrini, B., Hsieh, W.-., Erdjument-Bromage, H., Codega, P., Carro, M.S., Curiel-García, A., Campos, C., Pourmaleki, M., Grommes, C., Vivanco, I., et al. (2017). EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer. Nat commun, Vol.8 (1), p. 2035.  show abstract

Tanos, B.E., Perez Bay, A.E., Salvarezza, S., Vivanco, I., Mellinghoff, I., Osman, M., Sacks, D.B. & Rodriguez-Boulan, E. (2015). IQGAP1 controls tight junction formation through differential regulation of claudin recruitment. J cell sci, Vol.128 (5), pp. 853-862.  show abstract

Vivanco, I. (2014). Targeting molecular addictions in cancer. Br j cancer, Vol.111 (11), pp. 2033-2038.  show abstract

Vivanco, I., Chen, Z.C., Tanos, B., Oldrini, B., Hsieh, W.-., Yannuzzi, N., Campos, C. & Mellinghoff, I.K. (2014). A kinase-independent function of AKT promotes cancer cell survival. Elife, Vol.3.  show abstract

Vivanco, I., Robins, H.I., Rohle, D., Campos, C., Grommes, C., Nghiemphu, P.L., Kubek, S., Oldrini, B., Chheda, M.G., Yannuzzi, N., et al. (2012). Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer discov, Vol.2 (5), pp. 458-471.  show abstract

Graham, N.A., Tahmasian, M., Kohli, B., Komisopoulou, E., Zhu, M., Vivanco, I., Teitell, M.A., Wu, H., Ribas, A., Lo, R.S., et al. (2012). Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol syst biol, Vol.8, p. 589.  show abstract

Veeriah, S., Taylor, B.S., Meng, S., Fang, F., Yilmaz, E., Vivanco, I., Janakiraman, M., Schultz, N., Hanrahan, A.J., Pao, W., et al. (2010). Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat genet, Vol.42 (1), pp. 77-82.  show abstract

Peng, L., Wu, T.-., Tchieu, J.H., Feng, J., Brown, H.J., Feng, J., Li, X., Qi, J., Deng, H., Vivanco, I., et al. (2010). Inhibition of the phosphatidylinositol 3-kinase-Akt pathway enhances gamma-2 herpesvirus lytic replication and facilitates reactivation from latency. J gen virol, Vol.91 (Pt 2), pp. 463-469.  show abstract

Vivanco, I., Rohle, D., Versele, M., Iwanami, A., Kuga, D., Oldrini, B., Tanaka, K., Dang, J., Kubek, S., Palaskas, N., et al. (2010). The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc natl acad sci u s a, Vol.107 (14), pp. 6459-6464.  show abstract

Vivanco, I. & Mellinghoff, I.K. (2010). Epidermal growth factor receptor inhibitors in oncology. Curr opin oncol, Vol.22 (6), pp. 573-578.  show abstract

Chmielecki, J., Foo, J., Somwar, R., Regales, L., Vivanco, I., Shen, R., Michor, F. & Pao, W. (2009). EGFR T790M decreases growth potential of lung tumor cells with drug-sensitive EGFR mutant alleles in the absence of drug selection. Cancer research, Vol.69.

Veeriah, S., Brennan, C., Meng, S., Singh, B., Fagin, J.A., Solit, D.B., Paty, P.B., Rohle, D., Vivanco, I., Chmielecki, J., et al. (2009). The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc natl acad sci u s a, Vol.106 (23), pp. 9435-9440.  show abstract

Regales, L., Gong, Y., Shen, R., de Stanchina, E., Vivanco, I., Goel, A., Koutcher, J.A., Spassova, M., Ouerfelli, O., Mellinghoff, I.K., et al. (2009). Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J clin invest, Vol.119 (10), pp. 3000-3010.  show abstract

Meng, S., Arbit, T., Veeriah, S., Mellinghoff, I.K., Fang, F., Vivanco, I., Rohle, D. & Chan, T.A. (2009). 14-3-3sigma and p21 synergize to determine DNA damage response following Chk2 inhibition. Cell cycle, Vol.8 (14), pp. 2238-2246.  show abstract

Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P.A., Sawyers, C.L. & Wu, H. (2007). Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer res, Vol.67 (13), pp. 6083-6091.  show abstract

Vivanco, I., Palaskas, N., Tran, C., Finn, S.P., Getz, G., Kennedy, N.J., Jiao, J., Rose, J., Xie, W., Loda, M., et al. (2007). Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer cell, Vol.11 (6), pp. 555-569.  show abstract

Beroukhim, R., Getz, G., Nghiemphu, L., Barretina, J., Hsueh, T., Linhart, D., Vivanco, I., Lee, J.C., Huang, J.H., Alexander, S., et al. (2007). Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc natl acad sci u s a, Vol.104 (50), pp. 20007-20012.  show abstract

Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P.A., Sawyers, C.L. & Wu, H. (2007). Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development (vol 67, pg 6083, 2007). Cancer research, Vol.67 (16), pp. 7937-7937.

Lee, J.C., Vivanco, I., Beroukhim, R., Huang, J.H., Feng, W.L., DeBiasi, R.M., Yoshimoto, K., King, J.C., Nghiemphu, P., Yuza, Y., et al. (2006). Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. Plos med, Vol.3 (12), p. e485.  show abstract

Wang, M.Y., Lu, K.V., Zhu, S., Dia, E.Q., Vivanco, I., Shackleford, G.M., Cavenee, W.K., Mellinghoff, I.K., Cloughesy, T.F., Sawyers, C.L., et al. (2006). Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer res, Vol.66 (16), pp. 7864-7869.  show abstract

Lee, J.C., Vivanco, I., Beroukhim, R., Huang, J.H., Feng, W.L., DeBiasi, R.M., Yoshimoto, K., King, J.C., Nghiemphu, P., Yuza, Y., et al. (2006). Untitled. Toxicologic pathology, Vol.34 (7), pp. 1010-1010.

Mellinghoff, I.K., Wang, M.Y., Vivanco, I., Haas-Kogan, D.A., Zhu, S., Dia, E.Q., Lu, K.V., Yoshimoto, K., Huang, J.H., Chute, D.J., et al. (2005). Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N engl j med, Vol.353 (19), pp. 2012-2024.  show abstract

Mellinghoff, I.K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J. & Sawyers, C.L. (2004). HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer cell, Vol.6 (5), pp. 517-527.  show abstract

Vivanco, I. & Sawyers, C.L. (2002). The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nature reviews cancer, Vol.2 (7), pp. 489-501.

Vivanco, I. & Sawyers, C.L. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat rev cancer, Vol.2 (7), pp. 489-501.

Jain, A., Lam, A., Vivanco, I., Carey, M.F. & Reiter, R.E. (2002). Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol endocrinol, Vol.16 (10), pp. 2323-2337.  show abstract

Afar, D.E., Vivanco, I., Hubert, R.S., Kuo, J., Chen, E., Saffran, D.C., Raitano, A.B. & Jakobovits, A. (2001). Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia. Cancer res, Vol.61 (4), pp. 1686-1692.  show abstract

Hubert, R.S., Vivanco, I., Chen, E., Rastegar, S., Leong, K., Mitchell, S.C., Madraswala, R., Zhou, Y., Kuo, J., Raitano, A.B., et al. (1999). STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc natl acad sci u s a, Vol.96 (25), pp. 14523-14528.  show abstract

Raitano, A.B., Vivanco, I., Kuo, J., Hubert, R.S., Reiter, R.E., Witte, O.N., Jakobovits, A., Afar, D.E. & Saffran, D.C. (1999). Prostate stem cell antigen (PSCA): A target for cancer immunotherapy. Clinical cancer research, Vol.5, pp. 3761S-3761S.

Vivanco, I., Hubert, R.S., Chen, E., Rastegar, S., Leong, K., Mitchell, S.C., Madraswala, R., Zhou, Y.H., Kuo, J., Raitano, A.B., et al. (1999). Identification of a novel prostate-specific cell surface antigen highly expressed in human tumors. Clinical cancer research, Vol.5, pp. 3761S-3761S.

Poon, E., Jamin, Y., Liang, T., Waltz, S., Kwok, C., Hakkert, A., Richards, M., Urban, Z., Thway, K., Zied, R., et al. Pharmacological blockade of MYCN in neuroblastoma using orally-bioavailable CDK inhibitors reveals an approach widely applicable to Myc-dependent cancers. Nature medicine, .  show abstract


Conferences

Stein, S., Zhao, R., Haeno, H., Vivanco, I. & Michor, F. (2018). Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients, JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, Vol.45, p.S104.

Hsieh, W.-., Oldrini, B., Erdjument-Bromage, H., Codega, P., Carro, M.S., Vivanco, I., Rohle, D., Campos, C., Bielski, C., Taylor, B., et al. (2017). Identification of Ran binding protein 6 as a novel negative regulator of EGFR and candidate tumor suppressor in glioblastoma, CANCER RESEARCH, Vol.77.

Hsieh, W., Oldrini, B., Erdjument-Bromage, H., Codega, P., Vivanco, I., Rohle, D., Campos, C., Bielski, C.M., Taylor, B.S., Tempst, P., et al. (2016). Identification of RAN binding protein 6 as EGFR feedback regulator and candidate tumor suppressor., MOLECULAR BIOLOGY OF THE CELL, Vol.27.